Horm Metab Res 2008; 40(1): 69-71
DOI: 10.1055/s-2007-1004528
Short Communication

© Georg Thieme Verlag KG Stuttgart · New York

Changes in Hepatic ApoAV Expression are not Required for the Rapid Triglyceride Lowering Effect of Fish Oil Diet in Rats

B. P. Hagerty 1 , F. G. Schaap 2 , M. Hermann 3 , B. Krenn 1 , C. Eder 1 , B. Dorfmeister 1 , H. Stangl 1 , W. Patsch 4 , W. Strobl 1
  • 1Department of Medical Chemistry, Center for Physiology, Pathophysiology and Immunology, Medical University of Vienna, Vienna, Austria
  • 2AMC Liver Center, Amsterdam, The Netherlands
  • 3Max F. Perutz Laboratories, Department of Biochemistry, Medical University of Vienna, Vienna, Austria
  • 4Institute for Laboratory Medicine, Paracelsus Private Medical University, Salzburg, Austria
Further Information

Publication History

received 27.03.2007

accepted 28.06.2007

Publication Date:
07 January 2008 (eFirst)


Diets rich in polyunsaturated ω-3 or ω-6 fatty acids (PUFA) reduce fasting and postprandial plasma triglyceride levels by a rapid suppression of hepatic VLDL secretion and possibly by accelerated chylomicron clearance. ApoAV is a newly identified apolipoprotein of hepatic origin circulating bound to triglyceride rich lipoproteins and HDL at very low plasma levels [1] [2]. Human APOA5 polymorphisms are associated with elevated plasma triglycerides [1]. ApoAV deficiency leads to severe hypertriglyceridemia [3]. In genetically modified mice apoAV has a marked triglyceride-lowering effect due to stimulation of proteoglycan-bound lipoprotein lipase and possibly due to reduction of hepatic VLDL production [1] [4] [5] [6]. Thus, an increase of Apoa5 expression conceivably could play a role in the rapid triglyceride-lowering effect of diets rich in PUFA.

The present study was designed to determine whether Apoa5 gene expression is altered during the initial phase of a fish oil diet using rats adapted to a single meal per day. Apoa4, the apolipoprotein most homologous to apoAV, and Spot 14 (S14) a nuclear protein involved in lipogenesis were studied as controls. Both are suppressed transcriptionally by PUFA feeding [7] [8].


  • 1 Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM. Science. 2001;  294 169-173
  • 2 Vliet HN van der, Sammels MG, Leegwater AC, Levels JH, Reitsma PH, Boers W, Chamuleau RA. J Biol Chem. 2001;  276 44512-44520
  • 3 Oliva CP, Pisciotta L, Li Volti G, Sambataro MP, Cantafora A, Bellocchio A, Catapano A, Tarugi P, Bertolini S, Calandra S. Arterioscler Thromb Vasc Biol. 2005;  25 411-417
  • 4 Fruchart-Najib J, Bauge E. Biochem Biophys Res Commun. 2004;  319 397-404
  • 5 Schaap FG, Rensen PC, Voshol PJ, Vrins C, Vliet HN van der, Chamuleau RA, Havekes LM, Groen AK, van Dijk KW. J Biol Chem. 2004;  279 27941-27947
  • 6 Merkel M, Loeffler B, Kluger M, Fabig N, Geppert G, Pennacchio L, Laatsch A, Heeren J. J Biol Chem. 2005;  280 21553-21560
  • 7 Jump DB, Clarke SD, MacDougald O, Thelen A. Proc Natl Acad Sci USA. 1993;  90 8454-8458
  • 8 Strobl W, Knerer B, Gratzl R, Arbeiter K, Lin-Lee YC, Patsch W. J Clin Invest. 1993;  92 1766-1773
  • 9 Dorfmeister B, Brandlhofer S, Schaap FG, Hermann M, Fürnsinn C, Hagerty BP, Stangl H, Patsch W, Strobl W. Diabetologia. 2006;  49 1324-1332
  • 10 Weintraub MS, Zechner R, Brown A, Eisenberg S, Breslow JL. J Clin Invest. 1988;  82 1884-1893
  • 11 Grosskopf I, Baroukh N, Lee SJ, Kamari Y, Harats D, Rubin EM, Pennacchio LA, Cooper AD. Arterioscler Thromb Vasc Biol. 2005;  25 2573-2579
  • 12 Weinberg RB, Cook VR, Beckstead JA, Martin DD, Gallagher JW, Shelness GS, Ryan RO. J Biol Chem. 2003;  278 34438-34444
  • 13 Schuller E, Patel N, Item C, Greber-Platzer S, Baran H, Patsch W, Strobl W. Int J Obes Relat Metab Disord. 2000;  24 460-467


W. Strobl

Department of Medical chemistry, CPPI

Medical University of Vienna

Währingerstraße 10

1090 Vienna


Phone: +43/1/4277 608 22

Fax: +43/1/4277 608 81

Email: wolfgang.strobl@meduniwien.ac.at